Yale-NUS researchers discover drug cocktail that increases lifespan
A team of researchers led by Principal Investigator Dr Jan Gruber from Yale-NUS College has discovered a combination of pharmaceutical drugs that not only increases healthy lifespan in the microscopic worm Caenorhabditis elegans (C. elegans), but also delays the rate of ageing in them, a finding that could someday mean longer, healthier lives for humans.
The study, published in the peer-reviewed international journal Developmental Cell on 8 October 2018, lays crucial groundwork for further research into designing drug combinations that produce the same effect in mammals.
“Many countries in the world, including Singapore, are facing problems related to ageing populations,” said Dr Gruber, whose lab and research team made the discovery. “If we can find a way to extend healthy lifespan and delay ageing in people, we can counteract the detrimental effects of an ageing population, providing countries not only medical and economic benefits, but also a better quality of life for their people.”
Dr Gruber is an Assistant Professor of Science (Biochemistry) at Yale-NUS College and Assistant Professor at the Department of Biochemistry of the Yong Loo Lin School of Medicine at the National University of Singapore (NUS). The study was carried out by Dr Gruber’s research team in collaboration with researchers from the Singapore Lipidomics Incubator (SLING) at the Life Sciences Institute of NUS.
Dr Gruber’s team wanted to find out to what extent healthy lifespan could be extended by combining drugs targeting several pathways (underlying biological mechanisms) known to affect lifespan. For instance, the drug rapamycin is currently administered following organ transplants to prevent the body’s immune system from rejecting the transplanted organs, but previous experiments by other research groups showed that it extends the lifespan of many organisms, including the C. elegans worms, fruit flies and mice.
Dr Gruber’s team administered combinations of two or three compounds targeting different ageing pathways to C. elegans. Results showed that two drug pairs in particular extended the mean lifespan of the worms more than each of the drugs individually, and in combination with a third compound almost doubled mean lifespans. This effect is larger than any lifespan extension that has previously been reported for any drug intervention in adult animals.
The drug treatments had no adverse effect on the worm’s health. The researchers also discovered that across all ages, the treated worms were healthier and spend a larger percentage of their already extended lifespans in good health.
This is an important point for potential future human ageing interventions as increased health span, not just increased lifespan, would have significant medical and economic benefits. “We would benefit not only from having longer lives, but also spend more of those years free from age-related diseases like arthritis, cardiovascular disease, cancer, or Alzheimer’s disease,” Dr Gruber said. “These diseases currently require very expensive treatments, so the economic benefits of being healthier for longer would be enormous.” He cited a 2017 study that determined that if US citizens’ ageing rate was decreased by 20 percent, the US government would save US$7.1 trillion in public health costs over the next 50 years.
Dr Gruber’s lab also collaborated with Yale-NUS Associate Professor of Science (Life Science) Nicholas Tolwinski, who is also an Associate Professor with the Department of Biological Sciences at the NUS Faculty of Science, and found that a species of fruit flies (Drosophila melanogaster) treated with a similar drug cocktail also experienced significant lifespan extension. That two such evolutionarily-distinct organisms experience similar lifespan extensions suggests that the biological mechanisms that regulate these drug interactions on ageing are ancient, making it more likely that similar interactions between ageing pathways could be targeted in humans.
According to Dr Gruber, this study is a proof-of-principle, showing that pharmacological intervention targeting multiple ageing pathways is a promising strategy to slow ageing and dramatically extend healthy lifespan in adult animals.
The next steps for this research will focus on three large areas. The first will be to extend this approach with the aim of designing interventions even more effective than the ones developed in this study. The second area will involve determining the molecular and biological mechanisms of how the drugs interact to delay ageing and increase lifespan in order to develop computer models to simulate these interactions, allowing researchers to test thousands more combinations through computer modelling. The ultimate goal of this line of research would be to develop drug interventions safe enough slow ageing in humans, a goal that is also pursued by many other research teams around the world.
The Latest on: Lifespan
via Google News
The Latest on: Lifespan
- Hydralazine targets cAMP-dependent protein kinase leading to sirtuin1/5 activation and lifespan extension in C. eleganson October 28, 2019 at 3:14 am
Hydralazine is an FDA-approved drug used in the treatment of hypertension, heart failure and cancer. Hydralazine has been recently shown to promote lifespan in C. elegans, rotifer and yeast through a ...
- Dietary changes can improve health in old age and extend lifespanon October 27, 2019 at 9:01 pm
The pattern of the diet must be established earlier in life in order to improve health in old age and extend lifespan. The results of the study were published in the journal Nature Metabolism. But ...
- Photo Flash: THE LIFESPAN OF A FACT Heads to Stage Weston October 25, 2019 at 1:26 pm
Can you assume these days that what you see in the media is factually correct? Is accuracy all that important in an opinion piece? Those questions are central to the timely and very funny The Lifespan ...
- In this world of 'fake news' headlines, 'Lifespan of a Fact' is an absolute must-seeon October 25, 2019 at 10:41 am
In this world of 'fake news' headlines, 'Lifespan of a Fact' is an absolute must-see “The Lifespan of a Fact,” which opened Thursday at the Playhouse in the Park, takes us into the front lines of ...
- The average lifespan of a fiat currency isn’t 27 yearson October 23, 2019 at 10:30 pm
A crypto news site ran an intriguing story last week, under the headline “Bitcoin Has Already Reached 40% of Average Fiat Currency Lifespan”. We could hear the tiny sound of your eyeballs rolling to ...
- Pioneer Theatre Company Presents THE LIFESPAN OF A FACTon October 22, 2019 at 9:14 pm
The Broadway hit play The Lifespan of a Fact, based on the true story between essayist John D'Agata and fact-checker Jim Fingal, opens at Pioneer Theatre Company (PTC) November 1, 2019 and runs ...
- ‘The Lifespan of a Fact’ at the Rep is smart and timelyon October 19, 2019 at 11:55 am
Can strict adherence to reality get in the way of telling a good story? That’s the question raised in “The Lifespan of a Fact,” the smart and engagingly playful comedy-drama running through Nov. 10 in ...
- Q&A: In 'The Lifespan of a Fact,' a writer and editor clashon October 18, 2019 at 1:25 pm
That’s the timely question raised in “The Lifespan of a Fact,” the play running through Nov. 10 on the mainstage at the Repertory Theatre of St. Louis. Directed by Meredith McDonough, the comedy-drama ...
- Daily blue-light exposure shortens lifespan and causes brain neurodegeneration in Drosophilaon October 17, 2019 at 7:21 am
The LED technologies are relatively new; therefore, the long-term effects of exposure to blue light across the lifespan are not understood. We investigated the effects of light in the model organism, ...
via Bing News